Meet AZN Management: ESC 2025
Conference call and webcast for investors and analysts
31 August 2025
Meet AZN Management @ ESC - agenda
Furthering the AstraZeneca ambition Ruud Dobber, EVP, BioPharmaceuticals Business
Addressing unmet need in
cardiometabolic diseases
Sharon Barr, EVP, BioPharmaceuticals R&D
baxdrostat - Phase III BaxHTN:
baxdrostat in hard-to-control hypertension
Dr Bryan Williams, Chair of Medicine, University College London
Delivering next-wave of CVRM
growth with baxdrostat
Sharon Barr, EVP, BioPharmaceuticals R&D
Ruud Dobber, EVP, BioPharmaceuticals Business
Closing remarks and Q&A session
3
Furthering
the AstraZeneca ambition
Ruud Dobber
EVP, BIOPHARMACEUTICALS BUSINESS
Ambition - $80bn Total Revenue by 2030 & sustained
2030+ growth
Working on "today, tomorrow and the day after"
Illustrative only, not to scale
Launching key NMEs
$80bn
Beyond 2030
ADCs and Radioconjugates
Cell therapy and T-cell engagers Gene therapy
Existing portfolio
AZD0120
camizestrant rilvegostomig surovatamig
saruparib volrustomig AZN ADCs
Next-generation IO bispecifics
Weight management and risk factors
Calquence Datroway Enhertu
Imfinzi/Imjudo Tagrisso Truqap
AZD5004
baxdrostat dapa FDCs
laroprovstat tozorakimab
$54.1bn
Airsupra
Saphnelo
hMPV/RSV vaccine
IRA impact
Loss of Exclusivity
Breztri
Fasenra
Lokelma
Ultomiris
Tezspire
Wainua
efzimfotase alfa
gefurulimab
eneboparatide
Brilinta Farxiga
Lynparza
Soliris
2024
2030 Total Revenue ambition not dependent upon future M&A
2030
5 Note: Ambition to achieve $80bn in Total Revenue by 2030 is risk-adjusted, based on long-range plan as of AstraZeneca Investor Day May 2024. Medicines and assets listed reflect key contributors to 2030 Total Revenue ambition; however, this list is not exhaustive. Medicines and assets listed in alphabetical order and sorted by therapy area. Laroprovstat previously AZD0780. Collaboration partners: Daiichi Sankyo (Enhertu, Datroway), Amgen (Tezspire),
Ionis (Wainua), Compugen (rilvegostomig), Merck & Co., Inc. (Lynparza).
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
Disclaimer
AstraZeneca plc published this content on August 31, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 31, 2025 at 20:04 UTC.
